SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What makes MOG an absolute game-changer is our relentless dedication to memes and viral brilliance! We don't settle for mediocrity; we plunge into the realm of sheer awesomeness! Our community is a powerhouse of meme warriors, unleashing an unstoppable onslaught of viral memes that'll leave you in awe and stitches!  We're not here to play games; we're here to dominate! MOG is all about pushing the boundaries, smashing through barriers, and leaving our competitors eating our dust! Our passion for humor burns like an inferno, and we won't rest until the entire internet bows down to our meme supremacy!  And our community? It's a brotherhood, an unyielding powerhouse of support and camaraderie! When you're part of MOG, you're part of an unstoppable force, a family forged by the fire of meme revolution!  So, if you're ready to be part of the most intense, mind-bending memecoin movement ever conceived, then buckle up, strap in, and brace yourself! MOG is here to claim the throne, and we're taking no prisoners! Get ready to witness meme history in the making!

 MOG Coin

MOG Coin is trending amidst community excitement about potential gains, with some suggesting it could mirror past rallies. Bullish investors are actively buying and holding, while others debate whether it's a "scam" or a promising meme coin. Some traders are also pointing to a potential Robinhood listing on the horizon.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

VELO is trending amid discussions of its strategic partnerships, particularly within the defense and aerospace sectors, with community members highlighting potential growth catalysts. The company's collaborations with iRocket and its focus on U.S.-based manufacturing are sparking interest. Discussions also include the company's financial health, potential for profitability, and technical analysis of the stock.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class A

Berkshire Hathaway is trending as investors digest the news of Warren Buffett stepping down as CEO in 2026, while remaining Chairman.  Community discussion revolves around the implications for Berkshire's future, including potential shifts in investment strategy and capital allocation given its large cash position. Recent Q1 earnings, concerns about tariffs, and potential changes in corporate structure are also being discussed.

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics Inc

Protagonist Therapeutics ( $PTGX ) is trending due to positive Phase 2b trial results of Icotrokinra in ulcerative colitis, fueling speculation of a potential buyout by Johnson & Johnson ( $JNJ ). The community is actively discussing potential deal prices and the strategic fit for $JNJ , while analysts are raising price targets. Some traders are wary of overvaluation and potential pullbacks following the surge.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

NextDecade ($NEXT) is trending amid discussions around long-term price forecasts based on LNG prices and project milestones, with some community members projecting significant upside potential as trains come online; the stock is also garnering attention due to insider buying, positive news regarding its Rio Grande LNG project expansion, and speculation about potential catalysts. Community members are weighing the potential for $NEXT to become a major player in the LNG market, comparing it to Cheniere, while also discussing concerns around debt and potential delays.

AABG Token

AABBG is trending as investors discuss its potential, production updates, and recurring dividends, while others express concerns about timelines and dilution. Community members debate market manipulation and the company's execution, with some calling for patience and others demanding more transparency. Sentiment is mixed as shareholders await updates on financials, buybacks, and the AABB wallet.

BlackRock Institutional Trust Company N.A. - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF ($SOXX) is trending amid discussions about potential market overextension and reactions to Trump's proposed semiconductor tariffs, with community members debating the impact on specific companies. Some traders are expressing caution and considering bearish positions, while others remain bullish, citing ongoing demand and AI-driven growth. Discussions also involve potential shifts in market leadership and the cyclical nature of the semiconductor industry.

The Graph is an indexing protocol and global API for organizing blockchain data and making it easily accessible with GraphQL. Developers can use Graph Explorer to search, find, and publish all the public data they need to build decentralized applications. The Graph Network makes it possible to build serverless dApps that run entirely on public infrastructure.  GRT is the native token of the network that’s used to coordinate work. GRT is an ERC20 token. Node operators, called Indexers, stake and earn GRT for processing queries. Anyone can delegate GRT to Indexers to secure the network and earn rewards. Curators organize data on The Graph by signaling GRT on useful APIs, called subgraphs. Indexers, Delegators, and Curators work together to organize the data for the crypto economy and maintain a useful global API for DeFi and Web3.

The Graph

The Graph ($GRT) is trending as the community anticipates a potential surge, fueled by its relevance to AI and Web3. Discussions revolve around its undervalued status and speculation about upcoming moves, particularly regarding a collaboration with QMMM and potential breakout past key resistance levels, with some anticipating a rise reminiscent of previous cycles.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential to decentralize the internet and challenge cloud providers, drawing comparisons to Bitcoin's impact on traditional finance.  The launch of Caffeine AI is a key catalyst, though some express concerns over adoption and price movement, while others point to growing network usage and Bitcoin integration as bullish signals. Community debates include its long-term potential, criticisms of its tokenomics, and whether it can achieve mainstream adoption.

Chime Financial, Inc. engages in the design and development of a digital banking application. Its mobile app, Chime, provides online banking, fee-free overdraft, mobile banking, automatic savings, mobile payments, and security and control capabilities. The company was founded by Christopher R. Britt and Ryan King in 2012 and is headquartered in San Francisco, CA.

Chime Financial Inc - Ordinary Shares - Class A

Chime Financial, Inc.

Chime Financial ($CHYM) is trending amid mixed sentiment following recent performance, with community members debating whether its current price represents a buying opportunity or a value trap.  Discussions also focus on upcoming earnings and speculation about future growth catalysts. Some traders highlight potential value based on comparisons to competitors like SoFi, while others express concern over the stock's price decline since its IPO.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach...

Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as...

Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?

Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.

Amazon & Apple Lift Sentiment, Nvidia Hopes to Sell China Blackwell Chips  The Opening Trade 10/31

US stock futures advanced after strong earnings from Amazon and Apple. Amazon surged 12% in premarket trading on its fastest cloud-unit growth in nearly three years, while Apple gained on a revenue...

Amazon and Apple Results; Nvidia Hopes to Sell Blackwell Chips to China  Bloomberg Brief 10/31/2025

US equity futures rise as Amazon's results fueled a rebound in stocks with the company set for a $300 billion rally. Apple predicts a major sales surge during the holiday season after the release of...

<ul class="summary-bullets"><li>VKTX shares&nbsp;have surged&nbsp;about 45% in October,&nbsp;set for their strongest monthly gain of 2025.</li><li>Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.</li><li>Pfizer’s stalled Metsera deal and past struggles with its own obesity program added to speculation that Viking could become a future acquisition target.</li></ul>Viking Therapeutics shares have climbed nearly 45%&nbsp;in October, putting the stock on track for its best monthly performance of 2025, as investor excitement builds over its experimental obesity treatment and renewed analyst optimism.<h2 class="st-heading-2">Canaccord Starts Coverage With ‘Buy’&nbsp;</h2>Viking&nbsp;shares have rallied&nbsp;amid a slew of bullish analyst calls on Wall Street following quarterly earnings, with&nbsp;the latest coming from Canaccord Genuity’s initiation on Wednesday with a ‘Buy’ rating and $106 price target, representing an upside of 178% from the stock’s last close. The brokerage firm said Viking stands out as a leader in the obesity drug development space, citing its strong Phase 2 efficacy data from August for the oral version of VK2735.Canaccord expects readouts from Viking’s two Phase 3 trials in 2027 and mid-2028, and believes VK2735 can differentiate on multiple fronts in a crowded obesity drug pipeline.<h2 class="st-heading-2">Pfizer And Novo Nordisk Fuel M&amp;A Speculation</h2><a href="https://stocktwits.com/news-articles/markets/equity/retail-investors-expect-viking-therapeutics-to-bag-deal/cLGFym0R3xj">Investor chatter also intensified</a> after Novo Nordisk submitted an unsolicited proposal to acquire Metsera, a company that Pfizer had already agreed to purchase in September.Metsera has given Pfizer four business days to adjust its offer, fueling speculation among traders on Stocktwits that Pfizer might turn its attention to Viking if its Metsera deal falls through. Pfizer discontinued its own oral weight-loss candidate, Danuglipron, in April 2025, following safety issues, and has been seeking other ways to re-enter the obesity market.<h2 class="st-heading-2">Viking’s Obesity Drug Program</h2>Viking is developing VK2735, a dual agonist of the GLP-1 and GIP receptors, both of which play key roles in regulating glucose, appetite, and body weight. The company is testing subcutaneous and oral versions of the therapy in clinical trials.Early-stage data have shown positive safety and efficacy signals, reinforcing Wall Street’s belief that Viking could become a meaningful player in the weight-loss drug race dominated by Novo Nordisk and Eli Lilly.<h2 class="st-heading-2">Q3 Earnings And Outlook</h2>Viking Therapeutics reported a net loss of $52.3 million for the third quarter, in line with expectations, as it continues to invest heavily in its obesity and metabolic disease pipeline. Viking said it plans to meet with the U.S. Food and Drug Administration (FDA) by year-end to discuss advancing the oral formulation into late-stage clinical trials.The company noted that Phase III enrollment for its injectable version of VK2735 remains ahead of schedule, with completion expected in early 2026. A maintenance dosing study is currently underway to assess how best to sustain weight loss over time.&nbsp;Viking also plans to file an Investigational New Drug (IND) application with the FDA in the first quarter of 2026 for its next program targeting the amylin receptor, a mechanism that could complement GLP-1 and GIP therapies by improving appetite control and weight regulation.<h2 class="st-heading-2">Stocktwits Users See Viking At Center Of Pfizer–Novo Rivalry&nbsp;</h2>On Stocktwits, retail sentiment for Viking was ‘extremely bullish’ amid a 200% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:969/139;" src="https://news.stocktwits-cdn.com/vktx_ss_jpg_85eeea1fb9.webp" alt="vktx ss.jpg" width="969" height="139"><figcaption>VKTX sentiment and message volume as of October 31 | Source: Stocktwits</figcaption></figure>Some traders speculated that Novo Nordisk’s renewed bid for Metsera may be tied to competitive pressure from Viking’s obesity program. One bullish user&nbsp;<a href="https://stocktwits.com/biolover/message/634429740">suggested</a> Novo’s main interest in Metsera is its early-stage oral GLP-1/GIP agonist, adding that Novo knows Viking’s oral 2735 could be a long-term threat.<stembedurl>https://stocktwits.com/biolover/message/634429740</stembedurl>Another trader&nbsp;<a href="https://stocktwits.com/Bagholding_VKTX/message/634425707">agreed</a>,&nbsp;speculating Novo may have approached Viking before turning to Metsera, but “panicked” once Pfizer entered the picture. The user added that institutional investors may share the same view, noting Viking’s strong price reaction.<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/634425707</stembedurl><a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

Equity

CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?

CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.

<ul class="summary-bullets"><li>Novo Nordisk announced on Thursday that it has submitted an unsolicited proposal to acquire Metsera, following Pfizer's agreement to acquire the smaller obesity biopharmaceutical company in September.</li><li>Pfizer was previously developing its own oral weight-loss drug, Danuglipron, but discontinued its development in April 2025 due to liver enzyme elevations in patients.</li><li>The company is now looking to enter the booming obesity market with an acquisition. &nbsp;</li></ul>Retail investors on Stocktwits expect Pfizer to make an acquisition bid for Metsera’s rival, Viking Therapeutics, as the company’s agreed-upon deal with Metsera hangs in limbo.Danish drugmaker Novo Nordisk (NVO) <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-submits-revised-bid-for-metsera-enters-bidding-war-with-pfizer/cLGFsgdR3x2">announced</a> on Thursday that it has submitted an unsolicited proposal to acquire Metsera, Inc. (MTSR), following Pfizer's (PFE) agreement to acquire the smaller obesity biopharmaceutical company in September. Metsera has now given Pfizer four business days to negotiate potential adjustments to the existing transaction. The company also noted it would be entitled to terminate the Pfizer merger agreement if Novo’s proposal continues to constitute a superior proposal.&nbsp;“The best part would be if PFE lets NVO walk away with MTSR rather than up its own bid a few billion dollars, and instead makes a better offer to VKTX,” a Stocktwits user wrote.<stembedurl>https://stocktwits.com/spodero/message/634314721</stembedurl>Another sees Viking ending up with a good deal in time.<stembedurl>https://stocktwits.com/Idvst8/message/634311871</stembedurl>Shares of VKTX traded 10% higher at the time of writing. On Stocktwits, retail sentiment around VKTX stayed within the ‘bullish’ territory while message volume remained at ‘high’ levels.Pfizer was previously developing its own oral weight-loss drug, Danuglipron, but discontinued its development in April 2025 due to liver enzyme elevations in patients. The company is now looking to enter the booming obesity market with an acquisition.<h2 class="st-heading-2">Viking’s Obesity Program</h2>Viking, meanwhile, is evaluating both subcutaneous and oral formulations of its obesity program VK2735 in clinical trials. It is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both.In early and mid-stage trials, subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> is down 4% this year and approximately 46% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-cybertrucks-for-second-time-in-october-this-time-for-faulty-light-bar/cLGFud9R3xe">Tesla Recalls Cybertrucks For Second Time In October – This Time For A Faulty Light Bar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera 

Viking and Metsera are both attempting to develop drugs for the treatment of obesity.

BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View

Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.

What Analyst Projections for Key Metrics Reveal About Pfizer (PFE) Q3 Earnings

Evaluate the expected performance of Pfizer (PFE) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

PFE
Pfizer Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PFE News

PFEPfizer Inc